Generics vs. the Giant
For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…
Safeguarding against Stock-Outs
The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…
The Road to Treatment Access
Generic drug registration, licensing, and a trip to Gilead’s islands Karyn Kaplan and Tracy Swan Access to essential medicines is part of the human right to health. The HIV/AIDS epidemic has demonstrated that generic competition is key to massive antiretroviral…
A Drug by Any Other Name
The basics of generic medications, bioequivalence, and the push for good manufacturing practices Tim Horn Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global…
TAGline Fall 2014
Fool’s Errand: The Sloppy Science of the MDR-TB STREAM Trial
UPDATE: December 18, 2014 Sound Science of Redesigned STREAM Trial Investigators of the STREAM trial have successfully redesigned Stage 2 of the study to address concerns raised in the original article (below). Published in our Spring 2014 issue, this…
Punked by Pharma: Public Funds for Private Products
Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment? By Lindsay McKenna Motivating the pharmaceutical industry to step up and…
Better Late Than Never: Efavirenz Dose Optimization
After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles By Tim Horn and Polly Clayden…
Marketplace Menaces: Discriminatory Practices by the ACA’s Qualified Health Plans
Advocates scramble to stay ahead of coverage rejections, formulary concerns, and exorbitant out-of-pocket expenses facing people living with HIV By Kenyon Farrow #GetCovered That’s the White House’s official hashtag and marketing campaign to spike the number of Americans enrolling into…